Market capitalization | $6.62b |
Enterprise Value | $10.43b |
P/E (TTM) P/E ratio | 19.14 |
EV/FCF (TTM) EV/FCF | 9.98 |
EV/Sales (TTM) EV/Sales | 2.67 |
P/S ratio (TTM) P/S ratio | 1.69 |
P/B ratio (TTM) P/B ratio | 1.76 |
Revenue growth (TTM) Revenue growth | 3.91% |
Revenue (TTM) Revenue | $3.91b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
19 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
19 Analysts have issued a Jazz Pharmaceuticals Plc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 3,910 3,910 |
4%
4%
|
|
Gross Profit | 2,878 2,878 |
8%
8%
|
|
EBITDA | 1,298 1,298 |
12%
12%
|
EBIT (Operating Income) EBIT | 650 650 |
18%
18%
|
Net Profit | 395 395 |
557%
557%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Bruce Cozadd |
Employees | 2,800 |
Founded | 2005 |
Website | www.jazzpharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.